Biologic therapies are revolutionizing the treatment landscape for Behçet's uveitis (BU), demonstrating efficacy where conventional treatments have proven inadequate.

Despite their promising potential, biologic therapies also present unique challenges, including costs, accessibility, and adverse effects, requiring careful patient selection and ongoing monitoring.

TNF-α inhibitors, such as infliximab and adalimumab, have emerged as front-line therapies, with clinical trials showing strong efficacy in managing BU.

Continuous research and development efforts are essential to address the limitations of current biologic therapies as well as to explore novel potential therapeutic targets.

Global cooperation and meticulous data collection, via platforms like the AIDA International Registry, will significantly shape BU management, highlighting the potential of global health alliances.